ABSTRACT
Support is requested for a Keystone Symposia conference entitled Emerging Cellular Therapies at the
Forefront of Cancer Immunotherapy, organized by Drs. Francesco Marincola, Lisa Butterfield, David Stroncek
and Marcela Maus. The conference will be held in Banff, Alberta, Canada from January 29-February 2, 2023.
Cellular immunotherapy for the treatment of hematological malignancies and solid tumors is rapidly
progressing. Progress depends upon the development of better products that match the challenges limiting
effectiveness such as survival and engraftment, trafficking to cancer tissues, engagement with cancer cells,
and resilience to immune-suppressive factors while at the same time de-risking toxicity. This can be only
achieved following a holistic approach to achieve an optimal therapeutic index. Such estimation goes beyond
the selection of antigenic targets based of differential expression between benign and neoplastic tissues as is
intuitively done for small molecules, antibodies and other biologics where the engagement of the product with
its target is dependent on stable chemistry and predicable pharmacokinetics. Cell therapies instead are
affected by active rather than passive biodistribution, and context dependent potency. Thus, a broader range
of factors need to be considered like product-dependent variability (fitness, unpredictable pharmacokinetics
due non-specific trapping, sequestration and extravasation into normal tissues, and variable rates of in vivo
expansion). Individual cancer immune biology may affect differential trafficking to benign compared to
malignant tissues under different conditions of chemo-attraction, hampered engagement with cancer cells due
to physical or functional barriers, immune suppression, and cellular dysfunction due to unfavorable metabolic
conditions. This conference gathers expertise from all areas, to propose an integrated path forward to
successful implementation of novel cellular therapeutics, particularly for solid tumors.